DEFA14A: Regulus Therapeutics Updates Proxy Statement with Proxy Solicitor Details

Regulus Therapeutics amends its proxy statement to include details about its engagement with Alliance Advisors LLC for proxy solicitation.

Summary

• Regulus Therapeutics has issued a supplement to its definitive proxy statement filed on April 19, 2024.
• The supplement provides additional disclosures regarding the company's engagement of Alliance Advisors LLC to assist in proxy solicitation.
• Alliance Advisors LLC will be paid a fee of approximately $10,000 plus up to $5,000 for customary expenses.
• The company will bear the entire cost of soliciting proxies.
• Directors and employees may also solicit proxies without additional compensation.
• The supplement clarifies that it only modifies the information on page 4 of the original proxy statement and should be read in conjunction with the original document.
• Stockholders are urged to read the Proxy Statement and all related proxy materials carefully.
• Copies of the Supplement, the Proxy Statement and the annual report to stockholders are available at www.edocumentview.com/RGLS.

Sentiment

Score: 7

Explanation: The document is a routine update to a proxy statement, indicating normal corporate governance processes. The sentiment is neutral to slightly positive as it reflects transparency.

Positives

• The company is providing additional transparency by disclosing the details of its proxy solicitor engagement.

Industry Context

Proxy solicitation is a standard practice for publicly traded companies to ensure stockholder participation in important corporate decisions.

Comparison to Industry Standards

• The fees paid to Alliance Advisors LLC for proxy solicitation appear to be within the typical range for companies of similar size and complexity.
• Comparable companies often engage proxy solicitation firms to maximize shareholder turnout for annual meetings.

Stakeholder Impact

• Shareholders are provided with additional information to make informed voting decisions.

Next Steps

• Stockholders should review the supplement and the original proxy statement before voting.
• The Annual Meeting of Stockholders will be held on May 16, 2024.

Key Dates

Keywords

proxy solicitation, Regulus Therapeutics, Alliance Advisors LLC, proxy statement, annual meeting, stockholders